Medications

GlaxoSmithKline opts to hold on to HIV business

British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.

Medications

Soaring generic drug prices draw Senate scrutiny

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.

Medications

Gilead to license generic version of Sovaldi (Update)

Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000-per-pill hepatitis C drug Sovaldi for use in developing countries.

Medications

FDA approves first generic versions of Cymbalta

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

Medications

FDA seeks faster warning updates for generic drugs

The Food and Drug Administration is seeking a rule change to allow generic drugmakers to quickly update their warning labels with new safety information for doctors and patients.

Medications

Pfizer 2Q mixed, maintains 2013 outlook

Pfizer's second-quarter net income more than quadrupled, helped by the sale of its animal health business. The world's second-largest drugmaker beat Wall Street's earnings expectations, though revenue continued to decline ...

Medications

Pfizer painkiller gets longer patent protection (Update)

Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...

page 2 from 2